NASDAQ:INO Inovio Pharmaceuticals - INO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.79 -0.09 (-10.20%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.78▼$0.8850-Day Range$0.86▼$1.9152-Week Range$0.78▼$4.00Volume7.72 million shsAverage Volume4.48 million shsMarket Capitalization$206.07 millionP/E RatioN/ADividend YieldN/APrice Target$2.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Inovio Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold1.80 Rating ScoreUpside/Downside194.5% Upside$2.33 Price TargetShort InterestBearish15.19% of Shares Sold ShortDividend StrengthN/ASustainability-0.77Upright™ Environmental ScoreNews Sentiment0.83Based on 2 Articles This WeekInsider TradingSelling Shares$21,643 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.52) to ($0.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector340th out of 1,009 stocksSurgical & Medical Instruments Industry31st out of 103 stocks 2.9 Analyst's Opinion Consensus RatingInovio Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 1.80, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.33, Inovio Pharmaceuticals has a forecasted upside of 194.5% from its current price of $0.79.Amount of Analyst CoverageInovio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.19% of the outstanding shares of Inovio Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverInovio Pharmaceuticals has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Inovio Pharmaceuticals has recently decreased by 1.84%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInovio Pharmaceuticals does not currently pay a dividend.Dividend GrowthInovio Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInovio Pharmaceuticals has received a 77.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Clinical research services for cancer", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Inovio Pharmaceuticals is -0.77. Previous Next 2.7 News and Social Media Coverage News SentimentInovio Pharmaceuticals has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Inovio Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest35 people have searched for INO on MarketBeat in the last 30 days. This is an increase of 169% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -8% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inovio Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,643.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of Inovio Pharmaceuticals is held by insiders.Percentage Held by Institutions46.44% of the stock of Inovio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($0.52) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inovio Pharmaceuticals is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inovio Pharmaceuticals is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInovio Pharmaceuticals has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inovio Pharmaceuticals (NASDAQ:INO) StockInovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.Read More Receive INO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INO Stock News HeadlinesMarch 28, 2023 | americanbankingnews.comBrokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) PT at $2.00March 20, 2023 | americanbankingnews.comICU Medical (NASDAQ:ICUI) vs. Inovio Pharmaceuticals (NASDAQ:INO) Head-To-Head AnalysisMarch 30, 2023 | WealthPop (Ad)Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week)2023 is a classic “stock picker’s market.” The only way to beat these markets is to pick the right stocks at the right time. Legendary trader Adam Mesh is ready to hand you his best stock pick every week… It’s the same kind of research Wall Street’s top traders use to beat the markets. Click here to get his three top picks for right now to help get you started now. March 14, 2023 | marketwatch.comInovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitorsMarch 13, 2023 | marketwatch.comInovio Pharmaceuticals Inc. stock rises Monday, outperforms marketMarch 3, 2023 | finance.yahoo.comINOVIO to Present at the Oppenheimer 33rd Annual Healthcare ConferenceMarch 2, 2023 | msn.comInovio stock rises amid mixed trial results for cervical lesions drug; Q4 clinical updatesMarch 1, 2023 | msn.comInovio Pharmaceuticals GAAP EPS of -$1.17 misses by $0.06, revenue of $10.26M misses by $0.29MMarch 30, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 1, 2023 | markets.businessinsider.comWhy Inovio (INO) Shares Are Moving After-HoursMarch 1, 2023 | finance.yahoo.comInovio Pharmaceuticals (INO) Q4 2022 Earnings Call TranscriptFebruary 28, 2023 | marketwatch.comAll Vaccine Market Size Global Research Report, 2023 - 2029February 28, 2023 | marketwatch.comAll Vaccine Market Size Global Research Report, 2023 - 2029February 28, 2023 | marketwatch.comVaccine Market by Industry Applications, Competitive Landscape, SWOT Analysis by Upcoming Year 2028February 28, 2023 | marketwatch.comVaccine Market by Industry Applications, Competitive Landscape, SWOT Analysis by Upcoming Year 2028February 27, 2023 | marketwatch.comTransfection Technologies Market (New Insights Report) By 2023 which is Booming Strong Growth in the Globe till 2029February 25, 2023 | marketwatch.comZika Virus Therapeutics Market (New Insights Report) By 2023 which is Booming Strong Growth in the Globe till 2028February 24, 2023 | thestreet.comInovio Pharmaceuticals (INO) Optimistic on Zika/Ebola Vaccine ProgressFebruary 22, 2023 | marketwatch.comAnalysis of Needle Free Injection Market, Including Recent Developments, Potential Opportunities, and Predictions for 2028February 22, 2023 | marketwatch.comAll Vaccine Market (New Insights Report) By 2023 which is Booming Strong Growth in the Globe till 2028February 22, 2023 | marketwatch.comCovid-19 Vaccine Market International Business Analysis, Development Outlook and Regional Strategies 2028February 21, 2023 | marketwatch.comCervical Cancer Diagnostic Testing Market Size 2023 : Emerging Technologies, Opportunity and Forecast to 2028February 18, 2023 | marketwatch.comDNA Vaccination Market Analysis by Application like Hospitals, Research and Academic Laboratories, Others,)February 16, 2023 | marketwatch.comZika Virus Therapeutics Market Future Growth Insights, Share, Size, Scope, Emerging Technologies, Applications, Regions Forecast to 2028February 16, 2023 | finance.yahoo.comINOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory PapillomatosisFebruary 15, 2023 | finance.yahoo.comINOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023February 14, 2023 | finance.yahoo.comCoronavirus (COVID-19) Current Therapy Global Market Report 2023See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INO Company Calendar Last Earnings3/01/2023Today3/30/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INO CUSIPN/A CIK1055726 Webwww.inovio.com Phone(267) 440-4200Fax267-440-4242Employees317Year Founded1979Price Target and Rating Average Stock Price Forecast$2.33 High Stock Price Forecast$3.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+165.7%Consensus RatingHold Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-279,820,000.00 Net Margins-2,726.74% Pretax Margin-2,705.64% Return on Equity-98.03% Return on Assets-68.02% Debt Debt-to-Equity Ratio0.07 Current Ratio3.25 Quick Ratio3.25 Sales & Book Value Annual Sales$10.26 million Price / Sales22.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book0.99Miscellaneous Outstanding Shares260,130,000Free Float251,548,000Market Cap$228.45 million OptionableOptionable Beta1.09 Social Links Key ExecutivesJacqueline E. SheaPresident, Chief Executive Officer & DirectorPeter D. KiesChief Financial OfficerStephen KemmerrerSenior Vice President-Engineering DevelopmentLaurent M. HumeauChief Scientific OfficerJeffrey SkolnikSenior Vice President-Clinical DevelopmentKey CompetitorsQuipt Home MedicalNASDAQ:QIPTTELA BioNASDAQ:TELAAlpha Tau MedicalNASDAQ:DRTSClearPoint NeuroNASDAQ:CLPTProfound MedicalNASDAQ:PROFView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 22,051 shares on 3/23/2023Ownership: 0.037%ETF Managers Group LLCSold 11,396 shares on 3/23/2023Ownership: 0.024%David B WeinerSold 5,833 sharesTotal: $6,707.95 ($1.15/share)Voya Investment Management LLCSold 939,042 shares on 2/28/2023Ownership: 0.037%David B WeinerSold 11,668 sharesTotal: $14,935.04 ($1.28/share)View All Insider TransactionsView All Institutional Transactions INO Stock - Frequently Asked Questions Should I buy or sell Inovio Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares. View INO analyst ratings or view top-rated stocks. What is Inovio Pharmaceuticals' stock price forecast for 2023? 5 brokers have issued 12-month price objectives for Inovio Pharmaceuticals' shares. Their INO share price forecasts range from $2.00 to $3.00. On average, they predict the company's stock price to reach $2.33 in the next twelve months. This suggests a possible upside of 193.2% from the stock's current price. View analysts price targets for INO or view top-rated stocks among Wall Street analysts. How have INO shares performed in 2023? Inovio Pharmaceuticals' stock was trading at $1.56 at the beginning of 2023. Since then, INO stock has decreased by 49.0% and is now trading at $0.7957. View the best growth stocks for 2023 here. When is Inovio Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our INO earnings forecast. How were Inovio Pharmaceuticals' earnings last quarter? Inovio Pharmaceuticals, Inc. (NASDAQ:INO) issued its quarterly earnings results on Wednesday, March, 1st. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.06. The biopharmaceutical company earned $0.13 million during the quarter, compared to the consensus estimate of $0.46 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 98.03% and a negative net margin of 2,726.74%. During the same quarter in the previous year, the business posted ($0.50) EPS. What ETFs hold Inovio Pharmaceuticals' stock? ETFs with the largest weight of Inovio Pharmaceuticals (NASDAQ:INO) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ETFMG Treatments Testing and Advancements ETF (GERM), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).WisdomTree BioRevolution Fund (WDNA). When did Inovio Pharmaceuticals' stock split? Shares of Inovio Pharmaceuticals reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO? 12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees. What other stocks do shareholders of Inovio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT). What is Inovio Pharmaceuticals' stock symbol? Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO." Who are Inovio Pharmaceuticals' major shareholders? Inovio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.96%), Millennium Management LLC (1.73%), Renaissance Technologies LLC (1.03%), Bank of America Corp DE (0.99%), Charles Schwab Investment Management Inc. (0.75%) and Barclays PLC (0.54%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito. View institutional ownership trends. How do I buy shares of Inovio Pharmaceuticals? Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Inovio Pharmaceuticals' stock price today? One share of INO stock can currently be purchased for approximately $0.80. How much money does Inovio Pharmaceuticals make? Inovio Pharmaceuticals (NASDAQ:INO) has a market capitalization of $206.99 million and generates $10.26 million in revenue each year. The biopharmaceutical company earns $-279,820,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. How many employees does Inovio Pharmaceuticals have? The company employs 317 workers across the globe. How can I contact Inovio Pharmaceuticals? Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The official website for the company is www.inovio.com. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at investor.relations@inovio.com, or via fax at 267-440-4242. This page (NASDAQ:INO) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.